A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.
According to the Financial Times, Apple is ramping up its Apple News division. But can it fix its irritating AI hallucinations?
Nvidia, the chipmaking king, has announced a slew of consumer-focused hardware, including a $3,000 “personal AI supercomputer” called Digits.
The Wall Street watchdog is facing criticism from lawmakers, along with two lawsuits, that could theoretically redefine the agency.